Heartflow Inc
2 nominees · 2 ballot items.
Elect two Class I directors (Julie A. Cullivan and John C.M. Farquhar) and ratify PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Follow how the vote landed and what changed on Heartflow Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot2
- 1
Election of Directors — Two Class I Nominees (Julie A. Cullivan and John C.M. Farquhar
ManagementBoard: FORElect Julie A. Cullivan and John C.M. Farquhar as Class I directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified.
- 2
Ratification of the Appointment of the Independent Registered Public Accounting Firm (PricewaterhouseCoopers LLP
ManagementBoard: FORRatify the appointment of PricewaterhouseCoopers LLP as Heartflow’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Nominees on the ballot2
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | WELLINGTON MANAGEMENT GROUP LLP | 13.0% | 11,217,719 | $273M |
| 2 | Bain Capital Life Sciences Investors, LLC | 12.1% | 10,448,158 | $254M |
| 3 | FMR LLC | 5.2% | 4,487,741 | $109M |
| 4 | BAMCO INC /NY/ | 4.4% | 3,827,531 | $93M |
| 5 | JANUS HENDERSON GROUP PLC | 2.5% | 2,136,904 | $52M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4% | 2,045,938 | $50M |
| 7 | Invesco Ltd. | 2.2% | 1,901,177 | $46M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2% | 1,893,495 | $46M |
| 9 | ALLIANCEBERNSTEIN L.P. | 1.4% | 1,224,326 | $36M |
| 10 | MILLENNIUM MANAGEMENT LLC | 1.3% | 1,093,417 | $27M |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Heartflow Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Heartflow Inc 2026 annual meeting?
- Heartflow Inc (HTFL) holds its 2026 annual shareholder meeting on Tuesday, June 16, 2026.
- What is the record date for the Heartflow Inc 2026 meeting?
- The record date for the Heartflow Inc 2026 meeting is Friday, April 24, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Heartflow Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Heartflow Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Heartflow Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Heartflow Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.